natural compound + oral contraceptive pill for PCOS
A single follow-up comparison study suggests that a natural compound (Myo-Inositol) combined with OCP improves metabolic and hormonal parameters in PCOS adolescents.
Hypothesized mechanism
Mechanism not yet characterized in the substrate.
This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.
How the score was reached, for this pair
The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 5 of 10 overall, a emerging reading, from a direct rated emerging in strength.
The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.
Scored for women. Evidence generated in women (female population, ~100% female). (band F1, ×1.00).
Corroboration
Only a single primary study (a follow-up comparison) is cited, with no independent replication. A single primary study scores 0 by definition.
Rigor
The source is a follow-up comparison study, which appears to be a small comparative/observational trial in adolescents rather than a large RCT or meta-analysis. This corresponds to observational/small-trial rigor.
Specificity
The claim names both the intervention (natural compound—Myo-Inositol—combined with OCP) and the condition (PCOS) directly. The source title confirms PCOS teenagers and the specific therapies.
Plausibility
The claim asserts improvement of metabolic and hormonal parameters, which is mechanistically plausible for inositol/OCP therapy in PCOS, but no explicit mechanism is detailed or evidenced in the quote. Thus plausible but not evidenced.
Consistency
Only one study is presented, so directional consistency across sources cannot be assessed. Per rules, a single study is scored 1 (n/a, not penalized).
Layers not covered for this pair
Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.
More on the sex-specific pharmacokinetics layer and its sources →Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.
More on the cycle-phase layer and its sources →Source evidence · what the pipeline ingested
These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).
Every source below belongs to this signal’s evidence arm, Direct research. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.
- 1A therapy based on this natural compound alone or in combination with OCP seems effective to improve both metabolic and hormonal parameters of PCOS adolescents PubMed · PMID 34919250 ↗
These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.
The primary sources and pipelines this evidence is drawn from →